Downloaded from orbit.dtu.dk on: May 03, 2024



DTU Library

Risikovurdering af hyaluronsyre i kosttilskud

Poulsen, Morten

Publication date: 2020

Document Version
Publisher's PDF, also known as Version of record

Link back to DTU Orbit

Citation (APA):

Poulsen, M., (2020). Risikovurdering af hyaluronsyre i kosttilskud, No. 20/1001782, 2 p., Feb 07, 2020.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



DTU Doc nr. 20/1001782 FVST J. nr. 2019-29-7100-00074

> Dato 07.02.2020 MORP

Risikovurdering af hyaluronsyre i kosttilskud

Bestilling

Fødevarestyrelsen anmoder om en risikovurdering vedrørende tilsætningen af stoffet hyaluronsyre til kosttilskud.

Virksomheden oplyser i sin ansøgning, at der er tale om en tilsætning af 50 mg hyaluronsyre pr. anbefalet daglig dosis.

Konklusion

DTU Fødevareinstituttet vurderer, at et indtag på 50 mg hyaluronsyre per person per dag via kosttilskud ikke udgør en sundhedsmæssig risiko.

Risikovurdering

The hyaluronic acid in the present application is obtained from fermentation. However, Hyaluronic acid can also be derived from rooster combs and rooster comb extract (RCE) including hyaluronic acid was in 2013 assessed by EFSA.

The conclusion from the EFSA risk assessment was that a daily dose of 80 mg RCE was safe for adults. The hyaluronic acid assessed constituted 60-80% of the RCE, which corresponds to 48-64 mg hyaluronic acid per person per day. In the EFSA opinion, the target population was the general population, with the exception of pregnant women, children and people with adverse reactions to sodium hyaluronate and/or avian protein. These population groups are therefore not covered by the present assessment.

In their opinion, EFSA considered the nature of hyaluronic as well as data on nutrition, microbiology, toxicology, and allergenicity.

Human studies

EFSA included two randomised placebo-controlled human studies where RCE has been tested. The studies included some endpoints on safety and tolerability but were primarily designed to study possible beneficial effects of the RCE. EFSA concluded that due to the relatively low dose, the number of safety endpoints studied, and the limited information on



these safety endpoints, no conclusions about the safety of RCE from the human studies could be drawn.

Toxicological studies

In their opinion, EFSA referred to repeated dose studies in rodents ranging from 14 days to 13 weeks in duration. In these studies, rats were orally administered doses of 5 to 600 mg Rooster comb extract/kg body weight/day, and no compound-related adverse effects were reported. Based on these results, the NOAEL for the rooster comb extract was found to be 600 mg/kg body weight, which was the highest dose tested.

In the present application, the company applies for addition of 50 mg hyaluronic acid to a food supplement (corresponding to 0.71 mg/kg bw/day). This amount is in range with 48-64 mg hyaluronic acid per person per day, which was assessed as safe by EFSA.

Conclusion

This assessment is mainly based on the EFSA opinion and the supporting material in the application. It is assumed that the hyaluronic acid in the present application is similar to the hyaluronic acid obtained from rooster comb.

DTU Fødevareinstituttet finds that intake of 50 mg hyaluronic acid per person per day through a food supplement will not lead to any adverse health effects.

Benyttet litteratur

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2013. Scientific Opinion on Rooster Combs Extract. EFSA Journal 2013;11(6):3260, 22 pp. doi:10.2903/j.efsa.2013.3260

Canut et al., (2012) Genotoxicity, acute and subchronic toxicity studies in rats of a rooster comb extract rich in sodium hyaluronate. Regulatory Toxicology and Pharmacology, 62, 532-541.